Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Appl Toxicol ; 30(3): 226-32, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19885856

RESUMO

Humans can come into contact with thinner by occupational exposure or by intentional inhalation abuse. Numerous studies of workers for genotoxic effects of thinner exposure have yielded conflicting results, perhaps because co-exposure to variable other compounds cannot be avoided in workplace exposure studies. In contrast, there is no data concerning the genotoxic effects of intentional inhalation abuse. The aim of this project was to examine the genotoxic effects of thinner inhalation in an animal model of thinner abuse (rats exposed to 3000 ppm toluene, a high solvent concentration over a very short, 15 min time period, twice a day for 6 weeks). The data presented here provides evidence that thinner inhalation in our experimental conditions is able to induce weight loss, lung abnormalities and oxidative stress. This oxidative stress induces oxidative DNA damage that is not a characteristic feature of genotoxic damage. No significant difference in DNA damage and DNA repair (biomarkers of genotoxicity) in lymphocytes from thinner-treated and control rats was found. Lead treatment was used as a positive control in these assays. Finally, bone marrow was evaluated as a biomarker of cellular alteration associated with thinner inhalation. The observed absence of hemopoietic and genetic toxicity could be explained in part by the absence of benzene, the only carcinogenic component of thinner; however, benzene is no longer a common component of thinner. In conclusion, thinner did not cause genotoxic effects in an experimental model of intentional abuse despite the fact that thinner inhalation induces oxidative stress.


Assuntos
Reparo do DNA/efeitos dos fármacos , Modelos Animais de Doenças , Exposição por Inalação/efeitos adversos , Mutagênicos/toxicidade , Estresse Oxidativo/efeitos dos fármacos , Solventes/toxicidade , Transtornos Relacionados ao Uso de Substâncias/fisiopatologia , Animais , Biomarcadores/sangue , Biomarcadores/metabolismo , Peso Corporal/efeitos dos fármacos , Medula Óssea/efeitos dos fármacos , Medula Óssea/patologia , Dano ao DNA/efeitos dos fármacos , Pulmão/efeitos dos fármacos , Pulmão/metabolismo , Pulmão/patologia , Pneumopatias/sangue , Pneumopatias/induzido quimicamente , Pneumopatias/metabolismo , Pneumopatias/patologia , Linfócitos/efeitos dos fármacos , Linfócitos/metabolismo , Masculino , Malondialdeído/sangue , Malondialdeído/metabolismo , Oxirredução , Ratos , Ratos Sprague-Dawley , Solventes/administração & dosagem , Solventes/análise , Solventes/química , Transtornos Relacionados ao Uso de Substâncias/sangue , Transtornos Relacionados ao Uso de Substâncias/metabolismo , Transtornos Relacionados ao Uso de Substâncias/patologia , Fatores de Tempo , Tolueno/administração & dosagem , Tolueno/análise , Tolueno/toxicidade
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa